MedBright AI (Ticker: MBAI.c or MBAIF for US investors), recognizing the transformative potential of Artificial Intelligence (AI) in healthcare, actively invests in AI-focused companies.
Their flagship product, MedMatrix, employs AI to predict patient needs and optimize resource allocation in clinics, aiming to boost revenue, enhance patient satisfaction, and reduce physician burnout.
The dynamic matching feature is projected to increase clinic revenues by 10% without added costs, analyzing diverse data sources for predictions.
Yesterday, MBAI announced that it has closed its investment deal in the Limmi Healthcare AI Platform which is expected to be critical in the development of MBAI's MedMatrix Platform.
Under the agreement, MBAI issued 350 common shares of its US subsidiary, MB Acquisition Co., to Limmi in exchange for rights to Limmi's Artificial Intelligence FDA & HIPAA Platform. The shares are exchangeable for MBAI Class A Shares under certain conditions related to fundraising and gross profits.
Limmi also granted an option for MBAI to purchase the Limmi AI Platform by October 2025.
Notably, MBAI has done a great job of protecting existing shareholders, as under the agreement the shares that were issued likely won't come free trading for over 2 years.
Overall, the transactions align with MBAI's investment focus on healthcare AI technologies, adhering to its investment policy.
Full news here: https://ca.finance.yahoo.com/news/medbright-ai-announces-closing-investment-213000030.html
Posted on behalf of Medbright AI Investments Inc.